Compare ARK Space & Defense Innovation ETF (ARKX) vs Boston Scientific Corporation (BSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Space & Defense Innovation ETF vs Boston Scientific Corporation — how do they compare? ARK Space & Defense Innovation ETF trades at $31.79, while Boston Scientific Corporation trades at $45 (market cap $66.54B). The key difference: ARK Space & Defense Innovation ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| ARKX | BSX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $37.74 | $108.14 |
52-Week Low | $24.97 | $42.68 |
Market Cap | — | $66.54B |
Enterprise Value | — | $76.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARK Space Exploration & Innovation ETF (ARKX) trades at $32.05, down 0.82% today amid bearish technical signals. The ETF shows neutral oscillator readings but bearish moving averages, with key support at $32 and resistance at $33. Recent news highlights ARKX as a popular alternative to direct SpaceX investment, with the space economy reaching $500 billion in backlog according to 24/7 Wall Street (2026-07-06).
ARKX offers diversified exposure to the growing space sector without single-stock IPO risk. The ETF's higher volatility and expense ratio compared to traditional aerospace ETFs present both growth potential and increased risk. SpaceX's 8.31% weighting provides significant upside exposure but also concentration risk in a high-valuation name.
Boston Scientific (BSX) trades at $44.77, down 0.49% with a bearish technical signal despite strong fundamentals. The company shows robust revenue growth from $12.7B in 2022 to $20.1B in 2025, with net income margin expanding to 17.29%. Recent earnings beats and a 88% analyst buy rating contrast with the stock's 60% decline from its 2025 high, creating a significant valuation gap versus the $72.38 consensus target.
BSX presents a compelling value opportunity with attractive valuation metrics (P/E 18.73, P/S 3.25) and strong profitability, though investors face near-term technical weakness and competitive pressures in key segments like electrophysiology. The stock's current price represents a 38% discount to analyst targets, suggesting substantial upside potential for patient investors despite recent market skepticism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Space & Defense Innovation ETF
ARKX is an actively managed ETF that invests in companies leading space exploration and defense innovation. It focuses on orbital and sub-orbital aerospace, reusable rockets, and enabling technologies like AI, robotics, and satellite systems.
Read more on ARKX →About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →
